

Mongolia

Population 2018

3.2 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	14 (7–22)	428 (220–703)
HIV-positive TB incidence	0.015 (<0.01–0.039)	0.48 (0.08–1.2)
MDR/RR-TB incidence ^{oo}	0.72 (0.34–1.2)	23 (11–39)
HIV-negative TB mortality	0.33 (0.29–0.37)	10 (9.1–12)
HIV-positive TB mortality	<0.01 (<0.01–0.022)	0.27 (0.04–0.71)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	4.3% (3.3–5.6)
Previously treated cases	11% (8.2–14)

TB case notifications, 2018

Total new and relapse	3 880
- % tested with rapid diagnostics at time of diagnosis	39%
- % with known HIV status	70%
- % pulmonary	62%
- % bacteriologically confirmed ^{ooo}	74%
- % children aged 0–14 years	7%
- % women	40%
- % men	53%
Total cases notified	4 065

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	29% (17–56)
TB patients facing catastrophic total costs, 2017	70% (64–76)
TB case fatality ratio (estimated mortality/estimated incidence), 2018	3% (1–4)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	3	<1%
- on antiretroviral therapy	3	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	81%
- Previously treated cases	73%
Laboratory-confirmed cases*	MDR/RR-TB: 163, XDR-TB: 8
Patients started on treatment**	MDR/RR-TB: 204, XDR-TB: 8
MDR/RR-TB cases tested for resistance to second-line drugs	163

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	91%	4 002
Previously treated cases, excluding relapse, registered in 2017	78%	181
HIV-positive TB cases registered in 2017	86%	7
MDR/RR-TB cases started on second-line treatment in 2016	62%	241
XDR-TB cases started on second-line treatment in 2016	50%	4

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	7.4% (6.8–8.2)

TB financing, 2019

National TB budget (US\$ millions)	5.6
Funding source: 77% domestic, 23% international, 0% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Total TB incidence
— New and relapse TB cases notified
— HIV-positive TB incidence

(Rate per 100 000 population per year)




— HIV-negative TB mortality

Notified cases by age group and sex, 2018




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically